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Background/Aims: Chronic liver disease is a major wide-
spread cause of death, and whole liver transplantation is 
the only definitive treatment for patients with end-stage liver 
diseases. However, many problems, including donor short-
age, surgical complications and cost, hinder their usage. 
Recently, tissue-engineering technology provided a potential 
breakthrough for solving these problems. Three-dimensional 
(3D) printing technology has been used to mimic tissues 
and organs suitable for transplantation, but applications for 
the liver have been rare. Methods: A 3D bioprinting system 
was used to construct 3D printed hepatic structures using 
alginate. HepG2 cells were cultured on these 3D structures 
for 3 weeks and examined by fluorescence microscopy, his-
tology and immunohistochemistry. The expression of liver-
specific markers was quantified on days 1, 7, 14, and 21. 
Results: The cells grew well on the alginate scaffold, and 
liver-specific gene expression increased. The cells grew more 
extensively in 3D culture than two-dimensional culture and 
exhibited better structural aspects of the liver, indicating that 
the 3D bioprinting method recapitulates the liver architec-
ture. Conclusions: The 3D bioprinting of hepatic structures 
appears feasible. This technology may become a major tool 
and provide a bridge between basic science and the clinical 
challenges for regenerative medicine of the liver. (Gut Liver 
2017;11:121-128)
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INTRODUCTION
For patients suffering from end-stage liver disease including 
chronic liver fibrosis or alcoholic cirrhosis, whole liver trans-
plantation is the only definitive treatment. Although thousands 
of liver transplants have been performed over recent decades, 
most patients die while waiting their turn due to a shortage of 
livers for transplantation. To overcome this, many scientists 
have suggested the use of hepatocyte transplantation instead of 
liver organ transplantation. However, hepatocyte transplanta-
tion requires an unlimited source of hepatocytes. Furthermore, 
the utilization of primary hepatocytes has limitation by itself for 
the application due to their extremely slow proliferation, and is 
rarely optimal for long-term culture systems. 
To obtain a number of hepatocytes, direct differentiation 
technology using pluripotent stem cells (PSCs) has been de-
veloped.1-4 Since PSCs can replicate themselves infinitely and 
differentiate into most of cell types including hepatocytes, they 
are considered as an alternative cell source for supplying un-
limited number of hepatocytes for transplantation.5-8 However, 
although PSC-derived hepatocyte-like cells have representative 
features of primary hepatocytes, repopulation capacity in vivo, 
as well as restoration of the liver function,9-11 most researchers 
are aware of the inherent limitations of cells grown under two-
dimensional (2D) conditions.12-14
In general, tissues and organs have characteristic surfaces of 
unique shape, and are composed of cells interacting physiologi-
cally and biochemically. In order to better understand disease 
mechanisms and obtain cells for disease modelling and drug 
screening, three-dimensional (3D) structures are desirable15,16 
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since the true 3D microenvironment of target tissues and organs 
can never be mimicked by 2D models.
3D tissue-engineering technology has been advanced and 
considered to solve the problems of 2D culture system and bet-
ter capture the complexity of in vivo environments. As a gen-
eral rule, in 3D modelling the formation of a scaffold is a pre-
requisite step for reconstructing the unique structures of target 
tissues and organs for determining cell behavior and controlling 
physical cell-to-cell connections.17-19 Recently tissue-engineering 
methods combined with 3D printing technology have emerged 
as the most useful and efficient tools for producing compli-
cated scaffold structures.20-22 Therefore, 3D bioprinting tech-
nology may successfully mimic complicating complex organs 
with systemic 3D microarchitecture including liver suitable for 
transplantation, and eventually overcome a plenty of obstacles 
including donor shortage, surgical complications and exorbitant 
cost for liver transplantation.20-22
In the present study, we utilized 3D bioprinting technology 
for reconstructing liver tissues or organs. To achieve this goal, 
we used HepG2 cells, one of the liver cancer-derived cells to be 
applied to 3D printing technology. Newly fabricated, multiple 
layered-3D structures were efficiently modeled by mixing algi-
nate with HepG2 cells. Finally, we suggest that mimicking the 
3D hepatic structure by using 3D printing technology not only 
assists the HepG2 cells to stably repopulate, but also improves 
their gene expression profiles.
MATERIALS AND METHODS
1. Cell culture and maintenance
HepG2 cells, human hepatoblastoma cells derived from hepa-
tocellular carcinoma were cultured in in 75T Flasks in DMEM 
(11965; Gibco, Carlsbad, CA, USA) supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin (10378; Gibco) at 
37oC in a CO2 incubator. The medium was changed every 2 to 3 
days and the cells were used after about 14 passages.
2. Lentivirus production
Lentiviruses were produced as previously described. mCherry 
was packaged by cotransfection with psPAX2 lentiviral packag-
ing plasmid and pCMV-VSV-G plasmid in human embryonic 
kidney 293T cells. Culture supernatants were harvested after 48 
hours and 72 hours. The virus was resuspended in the culture 
medium, aliquoted and stored at –80oC. Lentiviral transduction 
of the mCherry was carried out in culture medium supplemented 
with 4 μg/mL polybrene.
3. Three-dimensional bioprinting of HepG2 cells with alginate
Three-dimensional printed strands of encapsulated cells were 
made with a 3D bioprinting system fabricated by the Korea In-
stitute of Machinery and Materials (KIMM). Before 3D printing, 
liver cells were prepared in 3% alginate solution. The nozzle 
size of the printer was 400 μm, the strand pitch was 1,000 μm 
and the 3D printed hydrogel structures measured 25 mm by 25 
mm. For cell printing, a continuous air pressure of 300 kPa was 
supplied to the dispenser, and cell-encapsulated alginate was 
extruded onto 10 cm2 culture dish. After printing, the 3D algi-
nate hydrogel was soaked with 1% calcium chloride solution for 
solid crosslinking, washed with phosphate buffered saline (PBS) 
and placed in HepG2 culture medium.
Table 1. Oligonucleotide Primers for Real-Time PCR
Gene Primer Primer Sequence (5′-3′) PCR product (bp)
Albumin Forward GCACAGAATCCTTGGTGAACAG 100
Reverse ATGGAAGGTGAATGTTTCAGCA
ASGR1 Forward CAGCAACTTCACAGCGACCA  96
Reverse AGCTGGGACTCTAGCGACTT
AFP Forward AGACTGCTGCAGCCAAAGTGA  80
Reverse GTGGGATCGATGCTGGAGTG
CK19 Forward TCCGAACCAAGTTTGAGACG 186
Reverse CCCTCAGCGTACTGATTTCC
Cyp1A2 Forward CGGACAGCACTTCCCTGAGA 124
Reverse AGGCAGGTAGCGAAGGATGG
TAT Forward TGGGGACCCTACTGTGTTTGG 105
Reverse ATGGATGGGGCATAGCCATT
GAPDH Forward TGCACCACCAACTGCTTAGC  87
Reverse GGCATGGACTGTGGTCATGAG
PCR, polymerase chain reaction; ASGR1, asialoglycoprotein receptor 1; AFP, alpha-fetoprotein; CK19, cytokeratin 19; Cyp1A2, cytochrome P450 
superfamily of enzymes 1A2; TAT, tyrosine amino-transferase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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4. Quantitative polymerase chain reaction analysis
Total RNAs were isolated using TRIZOL Reagent (Gibco) 
Samples of 2 μg RNA were reverse transcribed with a Transcrip-
tor First Strand cDNA Synthesis Kit (Roche; Branford, CT, USA), 
and real-time PCR was performed using 10 μL of LightCycler 
480 SYBR Green1 Master (Roche, Branford, CT, USA), 1 μL of 
cDNA and oligonucleotide primers, on an LC488 qPCR system 
(Roche). Reactions were carried out in triplicate; the primers 
used for human Albumin, ASGPR1, AFP, CK19, Cyp1A2, TAT 
and GAPDH are listed in Table 1. The PCR cycles consisted of 
45 cycles of 95oC, 60oC, and 72oC for 15 seconds each. Melting 
curves and melting peak data were obtained to characterize the 
PCR products. 
5. Immunocytochemistry
For immunofluorescence staining, cultured HepG2 cells were 
fixed in 4% paraformaldehyde in PBS for 15 minutes at room 
temperature. After washing three times with PBS, the cells were 
incubated with PBS containing 0.3% Triton X-100 (Sigma-
Aldrich, St. Louis, MO, USA) for 10 minutes at room tempera-
ture followed by blocking of nonspecific binding sites with 
5% goat serum (S-1000; Vector Laboratories, Inc., Burlingame, 
CA, USA) in PBS for 40 minutes. After washing, the samples in 
wells were incubated with primary antibodies as follows: rabbit 
antihuman albumin antibody (CL2513A; Cedarlane, Burlington, 
ON, Canada) and rabbit antihuman α-1-fetoprotein (A0008; 
DAKO, Glostrup, Denmark) in 350 μL of 2% goat serum at 4oC 
overnight. Next, they were incubated with goat antimouse or 
antirabbit secondary antibody for 1h. After washing, they were 
counterstained with 3 μM DAPI (D-1306; Invitrogen, Carlsbad, 
CA, USA) for 4 minutes with shaking 70 to 80 rpm. Cells in the 
culture dishes were mounted with mounting solution (0100-01; 
Southern Biotech, Birmingham, AL, USA), and examined under 
a fluorescence microscope or a Thermo confocal laser scanning 
microscope.
6. Hematoxylin & eosin staining and immunohistochemistry
Sections were deparaffinized by immersion in xylene for 10 
minutes and ethanol three times for 7 minutes, and stained with 
hematoxylin (Sigma-Aldrich) for 5 minutes. They were then 
counterstained with eosin for 1 minute, after washing with run-
ning water for 5 minutes. Finally, they were washed with run-
ning water and dehydrated in 95% ethanol for 5 minutes. 
The 3D printed mCherry-HepG2 alginate scaffolds were fixed 
in 4% buffered formalin and embedded in paraffin. Four-mi-
crometer thick sections were cut and mounted on silane-coated 
glass slides. All sections were deparaffinized and rehydrated 
with graded alcohols. After washing endogenous peroxidase 
was blocked with 3% H2O2 diluted in methanol for 15 minutes 
at room temperature. Antigen retrieval was performed by treat-
ing the slides in pH 6.0 citric acid buffer in an autoclave. The 
slides were incubated in a moist chamber with rabbit antihuman 
albumin antibody (CL2513A, 1:200; CEDARLANE), rabbit anti-
human α-fetoprotein (A0008, 1:200; DAKO), and Ki-67 (1:200), 
overnight at 4oC. After one day, the slides were washed with 
Tris buffer pH 7.6 and incubated with postantibody at room 
temperature for 30 minutes. After thorough washing, the slides 
were incubated with polymer for 30 minutes. After washing, the 
slides were incubated for 3 minutes with 3, 3′-diaminobenze-
dine tetrahydrochloride solution (0.05%) (DAB; Leica, Wetzlar, 
Germany) together with 0.03% hydrogen peroxide to produce 
a brown reaction product, counterstained with hematoxylin, 
washed in running tap water, then dehydrated, cleared and 
mounted. 
7. Statistical analysis
Quantitative data are presented as means±standard deviations 
(SD) and inferential statistics (p-values). Statistical significance 
was evaluated with two-tailed t-test with significance set at 
p<0.05, p<0.01, or p <0.001.
RESULTS
1. Morphology and characteristics of mCherry-tagged 
HepG2 cells 
Immortalized liver-derived cells such as HepG2 cells are con-
sidered ideal for studying drug metabolism due to their unlim-
ited availability and phenotypic stability. However, HepG2 cells 
exhibit relatively limited hepatic functionality compared with 
primary human hepatocytes in terms of genotoxic sensitivity, 
due to lack of drug-metabolizing enzymes, cytochromes (CYPs), 
and secretory functions as shown by relatively low expression 
of albumin, α-fetoprotein (AFP), and α-1 antitrypsin. Therefore, 
we mainly used HepG2 cells as a target cell source for improv-
ing their hepatic functionality in the current study. In conven-
tional 2D monolayer culture the HepG2 cells typically displayed 
epithelial cell-like morphology (Fig. 1A). The HepG2 cells tagged 
with the red fluorescent protein, mCherry, for effectively trac-
ing their localization and visualizing proliferative capacity were 
strongly positive for hepatic markers albumin and AFP (Fig. 
1B-D) indicating that they had basic hepatic features under 2D 
monolayer culture conditions.
2. Construction of 3D printed mCherry-HepG2 hepatic 
structures with alginate scaffolds 
In an attempt to improve the hepatic function of the HepG2 
cells, we used 3D bioprinting technology to construct 3D-
printed mCherry-HepG2 hepatic structures (Fig. 2A-E). The 
alginate was mixed with mCherry-HepG2 cells and extruded 
through nozzle pressure (Fig. 2B). After crosslinking, 25 mm×25 
mm structures were formed (Fig. 2C). Phase contrast microscope 
images revealed monolayers of compact HepG2 cells within the 
alginate scaffold of the designated pattern (Fig. 2D). mCherry-
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Fig. 1. Expression of hepatic genes 
in HepG2 cells. (A) Morphology of 
HepG2 cells grown in two-dimen-
sional culture. (B) HepG2 cells labeled 
with mCherry. (C, D) Immunofluores-
cence microscopy image of HepG2 
cells incubated with anti-ALBUMIN 
and anti-AFP antibodies (green). Nuclei 
are stained with DAPI. Bar, 100 μm.
C D
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Fig. 2. Construction of three-dimensional (3D) printed mCherry-HepG2 hepatic structures. (A) Instrument for 3D-bioprinting. (B) Alginate contain-
ing mCherry-HepG2 cells were extruded by nozzle pressure. (C) Cross-linked structures were deposited layer-by-layer in 25 mm×25 mm square 
arrays. (D) Phase contrast microscopy images of a confluent monolayer of HepG2 cells. Bar, 100 μm. (E) Fluorescence micrograph of mCherry-
HepG2 cells inside the alginate scaffold. Bar, 100 μm. (F) Multilayered mCherry-HepG2 cells repetitively solidified and layered upon each other. 
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expressing cells were observed inside the alginate scaffold under 
a fluorescence microscope (Fig. 2E). Multiple layers of mCherry-
HepG2 cells were constructed by repetitively adding and so-
lidifying monolayers to be intersected at right angles (Fig. 2F). 
Throughout 3D bioprinting method, we can readily establish 
3D-printed mCherry-HepG2 hepatic structures for mimicking 
liver architecture. 
3. Proliferation and repopulation of mCherry-HepG2 cells in 
3D-printed hepatic structure
Next, we have investigated whether the 3D-printed hepatic 
structures functionally assisted the HepG2 cells to proliferate 
and populate the structures. As expected, the number of mCher-
ry-HepG2 cells was stably amplified in time course manner (Fig. 
3A), and we confirmed the proliferation of the cells by fluores-
cence microscope images (Fig. 3B). The HepG2 cells appeared to 
be highly compact by days 14 and 21 after seeding, indicating 
that they stably proliferated and repopulated to form 3D-printed 
hepatic structures, as revealed by hematoxylin and eosin stain-
ing analysis (Fig. 3C). Surprisingly, the cells strongly expressed 
ALBUMIN, AFP, and also Ki-67, demonstrating that the highly 
proliferating HepG2 cells hold the typical hepatic property in 
3D-printed hepatic structure (Fig. 3D-F). These data suggest that 
the 3D-printed framework helps the HepG2 cells to proliferate 
without losing their hepatic identity.
4. Real-time PCR analysis of the 3D hepatic structures
Finally, we tested if the 3D structure improved the hepatic 
function of HepG2 cells in terms of gene expression. To the end, 
we evaluated the mRNA levels of the representative hepatic 
markers, ALBUMIN, ASGR1, and AFP. The expression of ASGR1 
and AFP had modestly increased by day 21 after seeding (Fig. 
4), but the expression of ALBUMIN had already increased sig-
nificantly after only 3 days of seeding (Fig. 4). Taken together, 
these data and those described previously show that the 3D-
printed structures not only assist the HepG2 cells to multiply 
but also enhance their hepatic function. 
Fig. 3. Proliferation of HepG2 cells in the three-dimensional (3D) culture system. (A1-5, B1-5) Bright field image of HepG2 cells grown in 3D cul-
ture (A1-5) and immunofluorescence image of HepG2 cells labeled with mCherry (B1-5). Bar, 500 μm. (C1-5, D1-5) Images of H&E staining (C1-5) 
and immunohistochemistry using antibodies against ALBUMIN (D1-5), AFP (E1-5), and Ki-67 (F1-5). Bar, 400 μm. The images were captured on 
days 1, 3, 7, 14, and 21 after seeding the HepG2 cells on 3D-printed scaffolds.
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DISCUSSION
End stage of liver diseases such as cirrhosis causes severe 
liver failure and portal hypertension. To deal with the liver fail-
ure at the end stage, liver transplantation is ultimately the only 
treatment at the terminal stages of disease, but the demand for 
liver transplantation is more than number of provision cadav-
eric livers or liver tissues from living donors. Therefore, human 
hepatocytes are considered as the most desirable source for the 
therapy, instead of liver organ transplantation. However, the 
transplantation of hepatocytes requires a number of cells in 
therapy, indicating that it needs an unlimited source of hepato-
cytes.23 
Due to infinite replication capacity and differentiation poten-
tial into most of cells and tissues in our body, PSCs including 
embryonic stem cells or induced PSCs are regarded as alterna-
tive cell sources for therapeutic applications such as regenera-
tive medicine and drug discovery. So far, many of strategies 
have been recently well developed for generating PSC-derived 
hepatocyte-like cells in vitro with high purity and maturity.1-4 
The PSC-derived hepatocyte-like cells hold typical characters 
of hepatocytes with primary hepatocytes in terms of secretory 
functions, xenobiotic activity and detoxification functions. 
Moreover, they are able to repopulate after transplantation in 
vivo and restore the liver functions.5,7-11,24
Although the strategies for obtaining pure and high quality of 
hepatocyte-like cells from PSCs have been improved, however, 
it cannot be perfectly ruled out the risk of oncogenicity origi-
nated from residually undifferentiated cells upon differentiation. 
To overcome this issue, direct conversion technology of which 
directly convert a terminally differentiated somatic cells into 
another types of cells in our interest without passing through 
pluripotent state has been reported. In recent, several groups 
successfully developed the protocols of generating hepatocyte-
like cells (so called as induced hepatocyte-like cells; iHeps) from 
somatic cells in human and mouse by ectopically expressing the 
defined sets of tissue-specific transcription factors.24-27 The iHeps 
also share hepatic properties with primary hepatocytes like as 
PSC-derived hepatocyte-like cells do in vitro.24-27 Similar with 
PSC-derived hepatocyte-like cells, the iHeps transplanted into 
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Fig. 4. Enhanced expression of hepatic markers in HepG2 cells in three-dimensional (3D) culture. Expression levels of the hepatic markers ALBU-
MIN, ASGPR1, AFP, CYP1A2, and TAT in HepG2 cells after culture under 3D conditions. The expression levels were normalized to those of mouse 
embryonic fibroblasts. *p<0.05; †p<0.01; ‡p<0.001.
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mouse liver failure model are capable of repopulating the liver 
and restores normal liver structure without fusion with recipient 
cells.24-27
For many years, 2D culture systems have been widely used 
in biological research and drug screening. However, since 2D 
culture system cannot truly mimic the physiological environ-
ment in 3D tissues and organs including liver, the cells cultured 
in 2D inevitably lacks the micro-environmental influences pres-
ent in natural 3D tissues.22,28 This factor has contributed to the 
poor predictive power of preclinical cell-based drug and toxicity 
screening assays.22,29,30 Furthermore, most candidate drugs pass-
ing through in vitro preclinical trials have failed to meet the 
desired efficacy or safety margins prior to entering subsequent 
clinical trials, perhaps partly for the same reason. To overcome 
the limitation of 2D culture system, 3D bioprinting culture mod-
els has been developed, which can reproduce true 3D pathologi-
cal architecture of tissue and organs by fabricating scaffolds 
with a novel micro- and macro-architecture.22 Recently, Duan 
et al.31 have described 3D bioprinted aortic valve conduits com-
posed of dual cell types, aortic root sinus smooth muscle cells 
(SMCs) and aortic valve leaflet interstitial cells (VICs), using 
fabricated alginate/gelatin hydrogel discs. Both SMCs and VICs 
were able to survive for over 7 days and displayed elevated 
levels of alpha-smooth muscle actin and vimentin expression, 
respectively. These results suggest that constructing 3D culture 
environment and fabricating natural structure complexity with 
cellular heterogeneity can be achieved by 3D bioprinting tech-
nology.
In the current study, we utilized 3D printing technology for 
mimicking liver tissues or organs.32-34 Multilayered-3D hepatic 
structures were efficiently constructed by mixing the alginate 
with HepG2 cells. As a consequence, we observed that mimick-
ing the 3D hepatic structure via 3D printing technology herein 
not only assists the HepG2 cells to stably repopulate, but also 
improves their gene expression profiles. Taken together, our 
findings show that 3D bioprinting of liver tissue suitable for 
transplantation may be a realistic option for overcoming the 
problems of donor shortage and surgical complications and 
thereby offer a new paradigm in the field of liver regenerative 
medicine.
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